{
    "clinical_study": {
        "@rank": "58974", 
        "brief_summary": {
            "textblock": "The purpose of this study is to determine the relative bioavailability of ReFacto AF as\n      compared to ReFacto, when each is administered as 2-minute bolus infusions."
        }, 
        "brief_title": "Study Evaluating BDDRFVIII and ReFacto AF in Hemophilia A", 
        "completion_date": {
            "#text": "February 2003", 
            "@type": "Actual"
        }, 
        "condition": "Hemophilia A", 
        "condition_browse": {
            "mesh_term": "Hemophilia A"
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Severe hemophilia A (FVIII:C < 1% at local laboratory)\n\n          -  Previously treated patients (PTP) with at least 250 exposure days to any factor VIII\n             product\n\n          -  Age greater than or equal to 12 years\\\n\n        Exclusion Criteria:\n\n          -  The presence of any bleeding disorder in addition to hemophilia A\n\n          -  Concomitant therapy with immunosuppressant drugs (e.g., intravenous immunoglobulin\n             (IVIG), routine systemic corticosteroid use)\n\n          -  History of detectable factor VIII inhibitor"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "12 Years"
        }, 
        "firstreceived_date": "June 5, 2002", 
        "id_info": {
            "nct_id": "NCT00038935", 
            "org_study_id": "3082B1-305"
        }, 
        "intervention": {
            "intervention_name": "ReFacto AF", 
            "intervention_type": "Drug"
        }, 
        "intervention_browse": {
            "mesh_term": "Factor VIII"
        }, 
        "keyword": "Hemophilia", 
        "lastchanged_date": "April 18, 2008", 
        "official_title": "A Single Dose, Randomized, Double-Blind, 2-Period Crossover Study in Patients With Hemophilia A to Evaluate the Pharmacokinetics of B-Domain Deleted Recombinant Human Factor VIII (BDDrFVIII) Manufactured by the Current Process (ReFacto) and by an Albumin Free Manufacturing Process (ReFacto AF)", 
        "overall_official": {
            "affiliation": "Wyeth is now a wholly owned subsidiary of Pfizer", 
            "last_name": "Medical Monitor, MD", 
            "role": "Study Director"
        }, 
        "overall_status": "Completed", 
        "oversight_info": {
            "authority": "United States: Food and Drug Administration"
        }, 
        "phase": "Phase 3", 
        "primary_completion_date": {
            "#text": "February 2003", 
            "@type": "Actual"
        }, 
        "removed_countries": {
            "country": "United States"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT00038935"
        }, 
        "source": "Wyeth is now a wholly owned subsidiary of Pfizer", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Wyeth is now a wholly owned subsidiary of Pfizer", 
                "agency_class": "Industry"
            }
        }, 
        "study_design": "Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Double-Blind, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "April 2008"
    }, 
    "geocoordinates": {}
}